Data gathered: November 27
AI Stock Analysis - Zymeworks (ZYME)
Analysis generated May 8, 2024. Powered by Chat GPT.
Zymeworks is a biopharmaceutical company based in Vancouver, Canada, focusing on the development of innovative protein-based therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. As a leader in bi-specific antibodies and other multi-functional therapeutics, the company is advancing a diverse pipeline of product candidates aimed at disrupting the landscape of clinical treatment. Zymeworks prides itself on its proprietary platforms that enable the design of highly-differentiated product candidates.
Stock Alerts - Zymeworks (ZYME)
 |
Zymeworks | November 22 Price is up by 5% in the last 24h. |
|
Zymeworks | November 21 Price is down by -5.8% in the last 24h. |
|
Zymeworks | November 15 Price is down by -5.4% in the last 24h. |
|
Zymeworks | November 14 Price is down by -5.6% in the last 24h. |
Alternative Data for Zymeworks
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 27 | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,419 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,348 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 308 | Sign up | Sign up | Sign up |
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Price | $14.42 |
| Target Price | Sign up |
| Volume | 193,990 |
| Market Cap | $978M |
| Year Range | $8.11 - $17.4 |
| Dividend Yield | 0% |
| PE Ratio | 3.56 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Bloom Burton Comments on Zymeworks FY2024 EarningsNovember 26 - ETF Daily News |
 |
Zymeworks (NYSE:ZYME) Given Neutral Rating at HC WainwrightNovember 25 - ETF Daily News |
Zymeworks - FDA Grants U.S. Approval of Ziihera for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive Biliary Tract CancerNovember 21 - Finnhub |
|
 |
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approvalNovember 21 - Biztoc.com |
Zymeworks Announces Participation in Upcoming Investor ConferencesNovember 21 - Financial Post |
|
Zymeworks : FDA Grants U.S. Approval of Ziihera® (zanidatamab hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2 positive (IHC 3+) Biliary Tract Cancer (BTC) Form 8 KNovember 21 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 16M | 14M | 2M | -30M | -33M | -0.390 |
| Q2 '24 | 19M | 16M | 3.6M | -38M | -42M | -0.270 |
| Q1 '24 | 10M | 16M | -6.2M | -32M | -37M | -0.420 |
| Q4 '23 | 16M | 15M | 880,000 | -14M | -23M | -0.200 |
| Q3 '23 | 17M | 17M | -200,000 | -29M | -33M | -0.410 |
Insider Transactions View All
| Moore Paul Andrew filed to sell 7,367 shares at $11.2. January 8 '24 |
| Astle Christopher filed to sell 6,503 shares at $11.2. January 8 '24 |
| Galbraith Kenneth filed to sell 23,762 shares at $11.2. January 8 '24 |
| Moore Paul Andrew filed to sell 9,706 shares at $10.7. January 8 '24 |
| Astle Christopher filed to sell 7,934 shares at $10.7. January 8 '24 |
Similar companies
Read more about Zymeworks (ZYME) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Zymeworks?
The Market Cap of Zymeworks is $978M.
What is Zymeworks' PE Ratio?
As of today, Zymeworks' PE (Price to Earnings) ratio is 3.56.
What is the current stock price of Zymeworks?
Currently, the price of one share of Zymeworks stock is $14.42.
How can I analyze the ZYME stock price chart for investment decisions?
The ZYME stock price chart above provides a comprehensive visual representation of Zymeworks' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Zymeworks shares. Our platform offers an up-to-date ZYME stock price chart, along with technical data analysis and alternative data insights.
Does ZYME offer dividends to its shareholders?
As of our latest update, Zymeworks (ZYME) does not offer dividends to its shareholders. Investors interested in Zymeworks should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Zymeworks?
Some of the similar stocks of Zymeworks are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.